Wada Noriaki, Kobayashi Hideyuki, Oka Shoichi, Ando Jiro, Tamura Hikaru
Dept. of Surgery, Ashikaga Red Cross Hospital.
Gan To Kagaku Ryoho. 2002 Nov;29(11):1935-42.
We studied a new chemoendocrine therapy against recurrent breast cancer in order to evaluate its efficacy and toxicity. Sixteen eligible patients were treated with the therapy consisting of adriamycin/cyclophosphamide (AC) plus toremifene (TOR). Adriamycin (20 mg/m2) was administered intravenously on days 1 and 8, and cyclophosphamide (100 mg/body) was given orally on days 1 to 14 every 4 weeks. TOR (120 mg/day) was given orally daily. The median age of the patients was 52 years; 6 were premenopausal and 10 postmenopausal. As post-operative adjuvant therapy, anthracycline chemotherapy and tamoxifen were given to 4 and 9 patients, respectively. AC therapy was administered for 8.5 cycles (median). Four complete responses (25%), 8 partial responses (37.5%), 4 no change (25%) (including 2 long NC), and 2 progressive disease (12.5%) were obtained, for an overall response rate of 62.5%. The median duration of time to progression and survival were 13.2 months (0.7-30.4 months) and 22.8 months (13.7-44.8 + months), respectively. The frequent toxicities were leukopenia, nausea/vomiting, and alopecia, but these were clinically well tolerated. Our results suggest that the addition of high dose TOR to AC therapy is useful in the treatment of recurrent breast cancer.
我们研究了一种针对复发性乳腺癌的新型化学内分泌疗法，以评估其疗效和毒性。16例符合条件的患者接受了由阿霉素/环磷酰胺（AC）加托瑞米芬（TOR）组成的治疗。阿霉素（20mg/m²）在第1天和第8天静脉注射，环磷酰胺（100mg/体）每4周在第1天至第14天口服。TOR（120mg/天）每日口服。患者的中位年龄为52岁；6例为绝经前，10例为绝经后。作为术后辅助治疗，分别有4例和9例患者接受了蒽环类化疗和他莫昔芬治疗。AC治疗进行了8.5个周期（中位数）。获得了4例完全缓解（25%）、8例部分缓解（37.5%）、4例病情无变化（25%）（包括2例长期病情无变化）和2例疾病进展（12.5%），总缓解率为62.5%。疾病进展时间和生存的中位持续时间分别为13.2个月（0.7 - 30.4个月）和22.8个月（13.7 - 44.8 +个月）。常见的毒性反应为白细胞减少、恶心/呕吐和脱发，但这些在临床上耐受性良好。我们的结果表明，在AC治疗中添加高剂量TOR对复发性乳腺癌的治疗是有用的。
